961 related articles for article (PubMed ID: 16712662)
61. Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer.
Fatourechi V; Hay ID; Javedan H; Wiseman GA; Mullan BP; Gorman CA
J Clin Endocrinol Metab; 2002 Apr; 87(4):1521-6. PubMed ID: 11932275
[TBL] [Abstract][Full Text] [Related]
62. Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma.
Nakanishi K; Kikumori T; Miyajima N; Takano Y; Noda S; Takeuchi D; Iwano S; Kodera Y
Clin Nucl Med; 2018 Jul; 43(7):482-485. PubMed ID: 29688947
[TBL] [Abstract][Full Text] [Related]
63. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
[TBL] [Abstract][Full Text] [Related]
64. The sodium-iodine symporter and the proton-pump inhibitors in - related to the side effects of- the treatment of thyroid cancer with iodine-131.
Sfakianakis G; Sfakianaki E
Hell J Nucl Med; 2007; 10(1):2-5. PubMed ID: 17450241
[TBL] [Abstract][Full Text] [Related]
65. Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results.
Simon D; Köhrle J; Schmutzler C; Mainz K; Reiners C; Röher HD
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():13-5. PubMed ID: 8980992
[TBL] [Abstract][Full Text] [Related]
66. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma.
Willhauck MJ; Sharif Samani BR; Klutz K; Cengic N; Wolf I; Mohr L; Geissler M; Senekowitsch-Schmidtke R; Göke B; Morris JC; Spitzweg C
Gene Ther; 2008 Feb; 15(3):214-23. PubMed ID: 17989705
[TBL] [Abstract][Full Text] [Related]
67. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
Liu J; Liu Y; Lin Y; Liang J
Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
[TBL] [Abstract][Full Text] [Related]
68. Clinical implications of diffuse hepatic uptake observed in postablative and post-therapeutic I-131 scans.
Omür O; Akgün A; Ozcan Z; Sen C; OzkiIiç H
Clin Nucl Med; 2009 Jan; 34(1):11-4. PubMed ID: 19092374
[TBL] [Abstract][Full Text] [Related]
69. The comparative effects of gene modulators on thyroid-specific genes and radioiodine uptake.
Tuncel M; Aydin D; Yaman E; Tazebay UH; Güç D; Doğan AL; Taşbasan B; Uğur O
Cancer Biother Radiopharm; 2007 Jun; 22(3):443-9. PubMed ID: 17679169
[TBL] [Abstract][Full Text] [Related]
70. Methylation status of genes in papillary thyroid carcinoma.
Smith JA; Fan CY; Zou C; Bodenner D; Kokoska MS
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1006-11. PubMed ID: 17938324
[TBL] [Abstract][Full Text] [Related]
71. Increased radioiodine uptake of thyroid cell cultures after external irradiation.
Meller B; Deisting W; Wenzel BE; Pethe A; Nadrowitz R; Meller J; Richter E; Baehre M
Strahlenther Onkol; 2006 Jan; 182(1):30-6. PubMed ID: 16404518
[TBL] [Abstract][Full Text] [Related]
72. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
Oh JM; Baek SH; Gangadaran P; Hong CM; Rajendran RL; Lee HW; Zhu L; Gopal A; Kalimuthu S; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2020 Apr; 30(4):501-518. PubMed ID: 31928162
[No Abstract] [Full Text] [Related]
73. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
[TBL] [Abstract][Full Text] [Related]
74. Treatment patterns of aging Americans with differentiated thyroid cancer.
Park HS; Roman SA; Sosa JA
Cancer; 2010 Jan; 116(1):20-30. PubMed ID: 19908255
[TBL] [Abstract][Full Text] [Related]
75. Endogenous thyrocyte-produced nitric oxide inhibits iodide uptake and thyroid-specific gene expression in FRTL-5 thyroid cells.
Fozzatti L; Vélez ML; Lucero AM; Nicola JP; Mascanfroni ID; Macció DR; Pellizas CG; Roth GA; Masini-Repiso AM
J Endocrinol; 2007 Mar; 192(3):627-37. PubMed ID: 17332530
[TBL] [Abstract][Full Text] [Related]
76. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.
Heemstra KA; Liu YY; Stokkel M; Kievit J; Corssmit E; Pereira AM; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2007 Jan; 66(1):58-64. PubMed ID: 17201802
[TBL] [Abstract][Full Text] [Related]
77. Effects of recombinant human thyroid-stimulating hormone superagonists on thyroidal uptake of 18F-fluorodeoxyglucose and radioiodide.
Reinfelder J; Maschauer S; Foss CA; Nimmagadda S; Fremont V; Wolf V; Weintraub BD; Pomper MG; Szkudlinski MW; Kuwert T; Prante O
Thyroid; 2011 Jul; 21(7):783-92. PubMed ID: 21568725
[TBL] [Abstract][Full Text] [Related]
78. Regulation of the sodium/iodide symporter by retinoids--a review.
Schmutzler C
Exp Clin Endocrinol Diabetes; 2001; 109(1):41-4. PubMed ID: 11573138
[TBL] [Abstract][Full Text] [Related]
79. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
Yang Z; Flores J; Katz S; Nathan CA; Mehta V
Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
[TBL] [Abstract][Full Text] [Related]
80. NIS and epithelial-mesenchymal transition marker expression of circulating tumor cells for predicting and monitoring the radioactive iodine-131 therapy effect in differentiated thyroid cancers.
Zheng L; Wang G; Guo W; Pan D; Xie L; He S; Luo C; Li H; Ran Y; Wu S; Liu F; Zhang X; Huang D
Mol Biol Rep; 2019 Aug; 46(4):4201-4212. PubMed ID: 31147861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
